This article is more than 5 years old. Information may no longer be current.

Glaukos acquires IOP sensor system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Glaukos has acquired an IOP sensor system from Dose Medical for $5.5 million in cash, according to a Glaukos press release.

The system has a microinvasive ocular implant designed to capture and store short-interval IOP measurements and transmit data to a physician. It also has a rechargeable battery.

Dose Medical, previously a wholly owned subsidiary of Glaukos, will also receive performance-based consideration of up to $9.5 million from Glaukos upon achievement of certain development, clinical and regulatory milestones in addition to the initial cash payment, the release said.

“Although still in an early development phase, the system offers future promise as a 24/7 tool for measuring the effects of glaucoma medical and surgical interventions, monitoring patient therapeutic compliance and managing disease progression,” Thomas Burns, president and CEO of Glaukos, said in the release. “Longer term, we also see opportunities to build upon the sensor platform with additional diagnostic and IOP management innovations.”